Explore more
News
(Reuters) -GSK shares fell more than 6% on Friday to the bottom of Britain's blue-chip index after a U.S. FDA advisory panel ...
In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...
The panelists flagged safety concerns with Blenrep and GSK’s failure to optimize its dosing regimen for the antibody-drug ...
GSK PLC closed 19.70% below its 52-week high of £16.79, which the company achieved on September 9th.
The Swedish defense company posted better-than-expected earnings and [raised its annual sales guidance]( ...
Administering Shingrix previously required combining a lyophilised antigen with a liquid adjuvant from two separate vials.
The panel expressed concerns about the proposed doses of Blenrep (belantamab mafodotin) in GSK's marketing application, ...
With GSK kicking its research and development engine into high gear in recent years, a shuffling of the scientific priorities ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback